Jason Harris

“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.

Findings shared during the 2022 International Kidney Cancer Symposium showed that patients with advanced renal cell carcinoma treated upfront with pembrolizumab plus lenvatinib were far less likely to need second-line therapy vs patients receiving first-line sunitinib.

The talazoparib/enzalutamide combination was also shown to have benefits in key secondary end points, including prostate specific antigen (PSA) response, time to PSA progression, and overall response rate.

TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in variant histology bladder cancer.

High genomic loss of heterozygosity may serve as a predictive marker for response to talazoparib in patients with metastatic castration-resistant prostate cancer.

“Not only does a deep PSA response identify patients who will have improved survival and progression-free outcomes, but also it is also associated with maintenance of health-related quality of life, improved patient reported physical wellbeing, and a reduced risk of worsening pain and fatigue intensity,” said Eric Jay Small, MD.

Patients treated with apalutamide achieved a PSA90 response at a 70.4% rate compared with 62.5% of patients who received enzalutamide at the end of the 12-month follow-up.

Magnetic resonance–guided focused ultrasound (MRgFUS) may be an effective alternative to radical therapy that improves outcomes for sexual function and urinary incontinence in men with intermediate-risk prostate cancer.

“The combination of TAR-200 and cetrelimab is being studied to determine whether it can improve patient outcomes,” says study coauthor Stephen B. Williams, MD, MS.

An analysis of three phase 3 trials highlighted the "obesity paradox" in prostate cancer.

The combination regimen shrank tumors and led to disease control in the majority of patients.